Skip to Main content Skip to Navigation
Journal articles

Intraocular pressure reduction and neuroprotection conferred by bone marrow-derived mesenchymal stem cells in an animal model of glaucoma

Abstract : Introduction : Glaucoma is a sight-threatening retinal neuropathy associated with elevated intraocular pressure (IOP) due to degeneration and fibrosis of the trabecular meshwork (TM). Glaucoma medications aim to reduce IOP without targeting the specific TM pathology, Bone-marrow mesenchymal stem cells (MSCs) are used today in various clinical studies. Here, we investigated the potential of MSCs therapy in an glaucoma-like ocular hypertension (OHT) model and decipher in vitro the effects of MSCs on primary human trabecular meshwork cells. Methods : Ocular hypertension model was performed by cauterization of 3 episcleral veins (EVC) of Long-Evans male rat eyes. MSCs were isolated from rat bone marrow, amplified in vitro and tagged with quantum dot nanocrystals. Animals were distributed as 1) MSCs group receiving 5.10 5 cells/6μl Minimum Essential Medium and 2) MEM group receiving 6μl MEM (n = 10 each). Injections were performed into the anterior chamber of 20 days-hypertensive eyes and IOP was monitored twice a week for 4 weeks. At the end of experiment, cell distribution in the anterior segment was examined in confocal microscopy on flat mounted corneas. Moreover, we tested in vitro effects of MSCs conditioned medium (MSC-CM) on primary human trabecular meshwork cells (hTM cells) using Akt activation, myosin phosphorylation and TGF-β 2 -dependent profibrotic phenotype in hTM cells. Results : We demonstrated a rapid and long-lasting in vivo effect of MSCs transplantation that significantly reduced IOP in hypertensive eyes induced by EVC. MSCs were located to the ciliary processes and the TM. Enumeration of RGCs on whole flat-mounted retina highlighted a protective effect of MSCs on RGCs death. In vitro, MSC-CM promotes: (i) hTM cells survival by activating the antiapoptotic pathway, Akt, (ii) hTM cells relaxation as analyzed by the decrease in myosin phosphorylation and (iii) inhibition of TGF-β 2 -dependent profibrotic phenotype acquisition in hTM cells. Conclusions : MSCs injection in the ocular anterior chamber in a rat model of OHT provides neuroprotective effect in the glaucoma pathophysiology via TM protection. These results demonstrate that MSCs constitute promising tool for treating ocular hypertension and retinal cell degeneration.
Document type :
Journal articles
Complete list of metadatas

Cited literature [48 references]  Display  Hide  Download
Contributor : Gestionnaire Hal-Upmc <>
Submitted on : Wednesday, September 23, 2015 - 12:13:27 PM
Last modification on : Monday, May 25, 2020 - 5:55:10 PM
Document(s) archivé(s) le : Tuesday, December 29, 2015 - 8:56:56 AM


s13287-015-0168-0 (1).pdf
Publication funded by an institution


Distributed under a Creative Commons Attribution 4.0 International License



Christophe Roubeix, David Godefroy, Céline Mias, Anaïs Sapienza, Luisa Riancho, et al.. Intraocular pressure reduction and neuroprotection conferred by bone marrow-derived mesenchymal stem cells in an animal model of glaucoma. Current Stem Cell Research & Therapy, Bentham Science Publishers Ltd, 2015, 6 (1), pp.177. ⟨10.1186/s13287-015-0168-0⟩. ⟨hal-01202543⟩



Record views


Files downloads